Results 151 to 160 of about 8,272 (178)

Immunoglobulin Light Chain and Systemic Light-Chain Amyloidosis

2007
Light-chain amyloidosis (AL) is characterized by the clonal expansion of plasma B cells that secrete large amounts of monoclonal immunoglobulin light chains. The free light chains circulate in serum and form amyloid fibrils on vital organs such as the kidney, heart, and liver causing organ failure and eventually death.
Marina Ramirez-Alvarado, Janelle K. De Stigter, Elizabeth M. Baden, Laura A. Sikkink, Richard W. McLaughlin, Anya L. Taboas   +5 more
openaire   +1 more source

Antibody‐based immunotherapy for treatment of immunoglobulin light‐chain amyloidosis

British Journal of Haematology, 2020
SummaryImmunoglobulin light‐chain (AL) amyloidosis is a clonal plasma cell disorder characterised by production and deposition of misfolded monoclonal light chains in vital organs with potential to cause irreversible organ damage. The treatment of AL amyloidosis has evolved along the lines of multiple myeloma (MM) owing to clonal plasma cells being at ...
Ricardo D. Parrondo, Umair Majeed, Taimur Sher   +2 more
openaire   +2 more sources

The Challenge of Systemic Immunoglobulin Light-Chain Amyloidosis (AL)

2012
The cardiac involvement and associated mortality that occur in systemic AL amyloidosis remain among the most challenging aspects of the systemic amyloid-related diseases. Monoclonal immunoglobulin light chains produced by a clone of plasma cells are usually the cause of symptoms and organ dysfunction via both poorly understood toxic effects of ...
PALLADINI, GIOVANNI, Comenzo, Raymond L.
openaire   +3 more sources

Flow cytometry in immunoglobulin light chain amyloidosis: Short review

Leukemia Research, 2015
Flow cytometry (FCM) has found its application in clinical diagnosis and evaluation of monoclonal gammopathies (MG). Although, research has been mainly focused on multiple myeloma (MM), nowadays FCM becomes to be potential tool in the field of AL amyloidosis.
Jana, Filipova, Lucie, Rihova, Pavla, Vsianska, Zuzana, Kufova, Elena, Kryukova, Fedor, Kryukov, Roman, Hajek   +6 more
openaire   +2 more sources

Diagnosis and Therapy of Immunoglobulin Light Chain Amyloidosis (AL Amyloidosis)

2012
Amyloidosis is a group of disorders that have in common the deposition of protein fibrils composed of protofibrils that have a crystallographic β(beta)-pleated sheet structure. Disease results from these proteinaceous deposits in one or more organ systems [1].
Morie A. Gertz, Robert A. Kyle
openaire   +1 more source

[Treatment strategy for immunoglobulin light chain amyloidosis].

[Rinsho ketsueki] The Japanese journal of clinical hematology, 2021
Systemic AL amyloidosis is a disease wherein amyloid proteins derived from monoclonal immunoglobulin light chains produced by abnormal plasma cells are deposited in the tissues through the whole body and cause organ failure. The treatment aims to minimize treatment-related toxicity and mortality to achieve a deeper and more persistent hematologic ...
openaire   +1 more source

Immunoglobulin Light Chain Amyloidosis

2018
Taxiarchis Kourelis, Morie A. Gertz
openaire   +1 more source

IMMUNOGLOBULIN LIGHT CHAIN AMYLOIDOSIS

2008
Morie A. Gertz, Suzanne R. Hayman
openaire   +1 more source

Immunoglobulin Light Chain Amyloidosis (Primary Amyloidosis)

2018
Morie A. Gertz, Francis K. Buadi, Martha Q. Lacy, Suzanne R. Hayman   +3 more
openaire   +1 more source

Mucocutaneous Xanthodermatosis as Initial Presentation of Immunoglobulin Light Chain Amyloidosis

The American Journal of Medicine, 2022
Aristeu Mascarenhas da Fonseca, Bruno Bom Furlan, Gustavo Palmer Irffi, Gustavo Brandão de Oliveira, Emanuella Graciott Souza, Suely Meireles Rezende   +5 more
openaire   +2 more sources